Rituximab as first-line treatment of patients with follicular lymphoma (FL) and a low-burden tumor: Clinical and molecular evaluation.

被引：0
|
作者：
Solal-Celigny, P
Salles, G
Brousse, N
Eftekhari, P
Soubeyran, P
Lacotte, L
Deconinck, E
Haioun, C
Foussard, C
Sebban, C
Stamatoulas, A
Milpied, N
Boue, F
Taillan, B
Lederlin, P
Najman, A
Mathieu-Boue, A
Benzohra, A
Colombat, P
机构：
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2802
引用
收藏
页码：631A / 631A
页数：1
相关论文
共 50 条
  • [31] Unmet needs in the first-line treatment of follicular lymphoma
    Casulo, C.
    Nastoupil, L.
    Fowler, N. H.
    Friedberg, J. W.
    Flowers, C. R.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2094 - 2106
  • [32] Follicular lymphoma: first-line selection criteria of treatment
    Nesterova, E. S.
    Kravchenko, S. K.
    Kovrigina, A. M.
    Gemdzhian, E. G.
    Plastinina, L., V
    Babaeva, F. E.
    Obukhova, T. N.
    Magomedova, A. U.
    Gaponova, T., V
    Kremenetskaya, A. M.
    Vorobyev, A., I
    TERAPEVTICHESKII ARKHIV, 2019, 91 (08) : 75 - 83
  • [33] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [34] Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL)
    Jankowitz, R. C.
    Foon, K. A.
    DeMonaco, N. A.
    Osborn, J.
    Wu, M.
    Evans, T.
    Swerdlow, S. H.
    Joyce, J.
    Land, S.
    Jacobs, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
    Zucca, Emanuele
    Rondeau, Stephanie
    Vanazzi, Anna
    Ostenstad, Bjorn
    Mey, Ulrich J. M.
    Rauch, Daniel
    Wahlin, Bjorn E.
    Hitz, Felicitas
    Hernberg, Micaela
    Johansson, Ann-Sofie
    Brown, Peter de Nully
    Hagberg, Hans
    Ferreri, Andres J. M.
    Lohri, Andreas
    Novak, Urban
    Zander, Thilo
    Bersvendsen, Hanne
    Bargetzi, Mario
    Mingrone, Walter
    Krasniqi, Fatime
    Dirnhofer, Stefan
    Hayoz, Stefanie
    Hawle, Hanne
    Vilei, Simona Berardi
    Ghielmini, Michele
    Kimby, Eva
    Caspar, Clemens
    Koberle, Dieter
    Novak, Urban
    Zenhausern, Reinhard
    Jost, Lorenz M.
    Mach, Nicolas
    Voegeli, Michele
    Tscherry, Georg
    Fischer, Natalie
    Burkhard, Roger
    Schmid, Mathias
    Panagiotis, Samaras
    Munksgaard, Lars
    Hernberg, Micaela
    Vasala, Kaija
    Lehtinen, Tuula
    Jyrkkio, Sirkku
    Ekanger, Roald
    Rolke, Jurgen
    Meyer, Peter
    Maisenholder, Martin
    Eidem, Monika
    Radlund, Anders
    Lagerlof, Ingemar
    BLOOD, 2019, 134 (04) : 353 - 362
  • [36] Rituximab as first-line systemic therapy for patients with low-grade lymphoma
    Hainsworth, JD
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 25 - 29
  • [37] Rituximab As First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular Lymphoma
    Croxtall, Jamie D.
    DRUGS, 2011, 71 (07) : 885 - 895
  • [38] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [39] Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
    Jain, Preetesh
    Zhao, Shuangtao
    Lee, Hun Ju
    Hill, Holly A.
    Ok, Chi Young
    Kanagal-Shamanna, Rashmi
    Hagemeister, Fredrick B.
    Fowler, Nathan
    Fayad, Luis
    Yao, Yixin
    Liu, Yang
    Moghrabi, Omar B.
    Navsaria, Lucy
    Feng, Lei
    Gonzalez, Graciela M. Nogueras
    Xu, Guofan
    Thirumurthi, Selvi
    Santos, David
    Iliescu, Cezar
    Tang, Guilin
    Medeiros, L. Jeffrey
    Vega, Francisco
    Avellaneda, Michelle
    Badillo, Maria
    Flowers, Christopher R.
    Wang, Linghua
    Wang, Michael L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 202 - +
  • [40] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
12345